PT - JOURNAL ARTICLE AU - Amant, Frédéric AU - Coosemans, An AU - Renard, Vincent AU - Everaert, Els AU - Vergote, Ignace TI - Clinical Outcome of ET-743 (Trabectedin; Yondelis) in High-Grade Uterine Sarcomas: Report on Five Patients and a Review of the Literature AID - 10.1111/IGC.0b013e31819c0f59 DP - 2009 Jan 01 TA - International Journal of Gynecologic Cancer PG - 245--248 VI - 19 IP - 2 4099 - http://ijgc.bmj.com/content/19/2/245.short 4100 - http://ijgc.bmj.com/content/19/2/245.full SO - Int J Gynecol Cancer2009 Jan 01; 19 AB - Abstract The clinical impact of ET-743 (trabectedin; Yondelis) in women with leiomyosarcoma and undifferentiated uterine sarcoma in patients previously treated with chemotherapy is investigated. Current data show a clinical benefit in 2/5 patients, of which 1 had a partial remission during 9 months. Pooling the treatment outcomes with literature data, a response in 5 (38%) of 13 patients and a clinical benefit in 7 (54%) of 13 patients for all high-grade uterine sarcomas is calculated. When only uterine leiomyosarcomas are concerned, response rate is 5 (45%) of 11 patients with a clinical benefit in 7 (64%) of 11 patients. These results on the use of ET-743 in uterine sarcoma patients support the conductance of larger trials.